Indication hub
Atrial Fibrillation clinical trials — Miami
Amavita Research is the GCSA-certified Miami cardiovascular trial site: TAVR-pioneer senior PI, an in-house South Florida heart practice, and a dedicated cardiovascular ASC.
Amavita Research has cardiac electrophysiology capability through Dr. Hans C. Rutzen-Lopez. No public atrial-fibrillation study is listed on the current homepage. Sponsors evaluating an AF protocol should start with Julio G. Martinez-Clark for first-touch, CDA, and NDA. Dr. Pedro Martinez-Clark is a principal investigator only.
Public studies
No public atrial fibrillation study is listed on the current Amavita Research homepage. New-sponsor first-touch, CDA, and NDA go to Julio G. Martinez-Clark (julio@amavita.health). Julio signs CDAs.
Investigators
- Dr. Hans C. Rutzen-Lopez, MD — Cardiac Electrophysiology — Sub-Investigator
- Dr. Pedro Martinez-Clark, MD, FACC — Principal Investigator
- Dr. William W. O'Neill, MD, FACC — Senior Principal Investigator
Why Amavita Research for atrial fibrillation
- Cardiac electrophysiology capability on staff for AF and arrhythmia protocol evaluation.
- One current research suite at 100 NW 170 Street, North Miami Beach. Kendall is opening — it is not a current site.
- Dedicated cardiovascular ASC at 9408 SW 87th Ave Suite 303.
- IAOCR GCSA recertified May 2026 through February 2027. ICH-GCP E6(R3).
New-sponsor first-touch
Julio G. Martinez-Clark
CEO, Amavita Research Services, LLC
New-sponsor first-touch, CDA, and NDA. Julio signs CDAs. Dr. Pedro Martinez-Clark is a principal investigator only. After a study is awarded, Nereisy Alonso, Sr CRC, COO owns study operations: monitors and start-up logistics.
Contact Julio about a protocolLocations
Where this work happens
- One North Miami Beach research suite at 100 NW 170 Street. This is the current research site of record.
- Dedicated cardiovascular ASC at 9408 SW 87th Ave Suite 303.
- Kendall is opening — it is not a current site.